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Background and purpose: Parkinson’s disease (PD), dementia with Lewy bod-
ies (DLB) and Alzheimer’s disease (AD) are three of the most common neu-
rodegenerative disorders. Up to 20% of these patients have the wrong
diagnosis, due to overlapping symptoms and shared pathologies. A cere-
brospinal ﬂuid (CSF) biomarker panel for AD is making its way into the
clinic, but an equivalent panel for PD and DLB and for improved diﬀerential
diagnoses is still lacking. Using well-deﬁned, community-based cohorts and
validated analytical methods, the diagnostic value of CSF total-a-synuclein
(t-a-syn) alone and in combination with total tau (t-tau) in newly diagnosed
patients with PD, DLB and AD was determined.
Methods: Cerebrospinal ﬂuid concentrations of t-a-syn were assessed using
our validated in-house enzyme-linked immunosorbent assay in 78 PD patients,
20 AD patients, 19 DLB patients and 32 controls. t-tau was measured using a
commercial assay. Diagnostic performance was assessed by receiver operating
characteristic curve analysis.
Results: Compared to controls (mean 517 pg/ml), signiﬁcantly lower levels of
CSF t-a-syn in patients with PD (434 pg/ml, 16% reduction, P = 0.036),
DLB (398 pg/ml, 23% reduction, P = 0.009) and AD (383 pg/ml, 26% reduc-
tion, P = 0.014) were found. t-a-syn levels did not diﬀer signiﬁcantly between
PD, DLB and AD. The t-tau/t-a-syn ratio showed an improved performance
compared to the single markers.
Conclusion: This is the ﬁrst study to compare patients with PD, DLB and
AD at the time of diagnosis. It was found that t-a-syn can contribute as a
teammate with tau in a CSF biomarker panel for PD and DLB, and
strengthen the existing biomarker panel for AD.
Introduction
Parkinson’s disease (PD), dementia with Lewy bodies
(DLB) and Alzheimer’s disease (AD) are three of the
most common neurodegenerative diseases worldwide.
Despite some fundamental diﬀerences in underlying
causes and pathologies, there is also a substantial
overlap of symptoms and pathological features [1,2].
Therefore, major challenges for the management of
PD, DLB and AD are diagnostic and prognostic inac-
curacy, which highlight the need for biomarkers to
aid in clinical decision making.
Correspondence: J. Lange, Norwegian Centre for Movement
Disorders, Stavanger University Hospital, Postboks 8100, 4068
Stavanger, Norway (tel.: +47 5151 5602; fax: +47 5151 5515, e-
mail: johannes.lange@sus.no).
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One of the pathological features that has been
observed most frequently in PD, DLB and AD is a-
synuclein (a-syn) aggregation into Lewy bodies (LBs)
[3]. LBs are best known for their role in PD and
DLB, hence termed synucleinopathies, but are also
found in up to 60% of all patients with AD upon
autopsy [4].
Cerebrospinal ﬂuid (CSF) a-syn has been proposed
as a biomarker for neurodegenerative diseases with
LB pathology. For PD, the majority of previous
studies report reduced CSF total-a-syn (t-a-syn)
levels in PD patients compared to controls [5,6].
However, the ﬁndings are inconsistent as several
studies showed no diﬀerences [6]. It has also been
suggested that t-a-syn may improve the diagnostic
and prognostic performance of the AD biomarker
panel [7]. The interest for a-syn in AD pathology
further increased with the notion that a-syn interacts
with amyloid-b (Ab) and tau to promote mutual
aggregation and thereby increase neurodegeneration
and worsen the prognosis [8]. Two meta-analyses
focusing on AD [9] and DLB [10] conclude that CSF
t-a-syn is signiﬁcantly higher in AD compared to the
other neurological disorders assessed, including PD
and DLB, but does not diﬀer signiﬁcantly between
AD and controls [9], DLB and controls or DLB and
PD [10]. However, the ﬁndings are inconsistent as
several studies report that t-a-syn did not diﬀerenti-
ate between DLB and AD [6].
The Investigating Synuclein Consortium [11] and
others have identiﬁed the need for further research,
speciﬁcally using well-deﬁned patient groups with uni-
form diagnostic criteria, validated assays and proper
pre-analytical sample handling. In the light of this,
CSF t-a-syn was measured using a validated in-house
enzyme-linked immunosorbent assay (ELISA) in
patients with PD, AD and DLB from two renowned
longitudinal cohort studies speciﬁcally designed for
the analysis of biomarkers.
Materials and methods
Study participants
The PD group consisted of 78 newly diagnosed, drug-
na€ıve patients from the Norwegian ParkWest study
[12], a prospective, population-based, longitudinal
cohort study investigating the incidence, neurobiology
and prognosis of PD. All met diagnostic criteria of
PD [13] at their ﬁnal study visit. Exclusion criteria
were atypical and secondary parkinsonism as well as
dementia development during the ﬁrst year of motor
onset to ensure exclusion of patients with DLB
and AD.
Cerebrospinal ﬂuid from 20 AD and 19 DLB
patients were obtained from the Norwegian DemWest
study, a prospective, longitudinal cohort study of
patients with suspected or newly diagnosed dementia
[14]. A diagnosis of AD was made according to the
National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association criteria [15], and a
diagnosis of DLB was made according to the Diagnos-
tic and Statistical Manual of Mental Disorders IV [16].
All patients met criteria of AD or DLB, respectively,
at their ﬁnal study visit.
All patients underwent comprehensive, standardized
clinical assessments by experienced movement disorder
and dementia experts [14,17]. Motor severity was
determined using the Uniﬁed Parkinson’s Disease Rat-
ing Scale (UPDRS) part III [18], and global cognition
was determined by the Mini-Mental State Examina-
tion (MMSE) [19]. For PD, disease stage was evalu-
ated using the Hoehn and Yahr scale [20].
The control group was a set of 32 subjects without
any known brain disease, who underwent elective neu-
rological examination or orthopaedic surgery at Sta-
vanger University Hospital. Only MMSE and
demographic data were obtained for the control
group.
Pre-analytical sample handling
Lumbar puncture and CSF collection was conducted
according to standardized procedures after overnight
fasting, as described previously [17]. Brieﬂy, the
freshly drawn CSF samples were centrifuged at 2000 g
for 10 min at 4°C, and frozen in polypropylene tubes
at 80°C. Prior to analysis, the samples were sub-
jected to one freeze–thaw event for aliquotation pur-
poses. The samples were thawed on ice and kept on
ice until analysis.
Total-a-syn and t-tau measurement
The CSF samples were analysed using our recently
developed and validated in-house t-a-syn ELISA, as
described before [21]. This assay recognizes the 140
amino acid monomeric form of a-syn and showed
high correlation with the BioLegend assay for t-a-syn
[21]. Plate-to-plate variation was below 9%. t-tau was
measured using a commercial kit (V-Plex; Meso Scale
Discovery, Rockville, MD, USA) according to the
manufacturer’s instructions. For three PD samples,
the t-tau concentration was below the detection limit
of the assay and they were therefore removed from
the analysis. The plate-to-plate variation was below
11.1%. All analyses were performed at the
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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Neuroscience Research Laboratory at Stavanger
University Hospital, Norway.
Haemoglobin measurement
To assess possible blood contamination as a source of
a-syn, the samples were analysed for haemoglobin
content using a commercial kit (Bethyl Laboratories,
Montgomery, AL, USA). Samples with haemoglobin
levels over 200 ng/ml were excluded from the study.
Statistical analysis
A four-parameter logistic ﬁt of standard curves as well
as calculation of t-a-syn and t-tau concentrations were
done with the Mesoscale Discovery Workbench 4.0
software (Meso Scale Discovery). Descriptive statistics
for continuous variables are presented as mean with
standard deviations. Categorical variables are pre-
sented as counts and percentages. Between-group
comparisons were performed with Kruskal–Wallis
tests for continuous variables or Pearson chi-squared
tests for categorical variables. The strengths of corre-
lations between continuous variables are presented as
Spearman’s rank correlation coeﬃcients. Between-
group comparisons for CSF data were determined by
ANCOVA followed by simple planned contrast analysis
entering log-transformed CSF values and adjusting
for age and sex. Primary comparisons were normal
controls (NCs) versus PD, DLB or AD. Secondary
comparisons were between PD, DLB and AD. Recei-
ver operating characteristic (ROC) curve analyses
were used to calculate the area under the curve
(AUC) and P values. AUC values were classiﬁed as
follows: 0.9–1.0 excellent, 0.8–0.9 good, 0.7–0.8 fair,
0.6–0.7 poor, and below 0.6 fail. Cut-oﬀ values were
determined using the Youden index. ROC curves were
plotted in Excel (Microsoft, Redmond, WA, USA).
All analyses were conducted using SPSS 24 (IBM,
Armonk, NY, USA). Two-tailed P values <0.05 were
considered statistically signiﬁcant.
Ethics
The study was approved by the Regional Committee
for Medical and Health Research Ethics. All partici-
pants provided written informed consent. This study
complies with the Declaration of Helsinki.
Results
In this study, a total of 149 subjects were included to
determine the ability of CSF t-a-syn alone and in
combination with t-tau to discriminate between
patients with newly diagnosed PD (n = 78), DLB
(n = 19) and AD (n = 20), as well as NCs (n = 32)
(group characteristics in Table 1). The mean t-a-syn
concentrations were signiﬁcantly lower in PD, DLB
and AD patients than in the control group
(P = 0.036, P = 0.009 and P = 0.014, respectively).
Amongst the disease groups, the mean t-a-syn concen-
trations were highest in PD, intermediate in DLB and
lowest in AD (Fig. 1a). However, the observed diﬀer-
ences between the three disease groups were not sig-
niﬁcant (all P > 0.253). t-tau was increased in the
AD group compared to controls (P = 0.050) and com-
pared to PD (P = 0.041, Fig. 1b). The DLB group
showed a similar pattern to AD, but the diﬀerences
were not statistically signiﬁcant.
There was a positive correlation between t-a-syn
and t-tau across all diagnostic groups (q = 0.696–
0.788, all P < 0.001, Table S1). Correlations of clinical
parameters (MMSE, UPDRS part III, disease dura-
tion and age) with t-a-syn and t-tau are presented in
Table 1 Demographic data and CSF concentrations
NCs PD DLB AD P value
Number of cases 32 78 19 20
Age (years) 67.9 (8.5) 66.5 (8.3) 73.3 (6.7) 73.3 (10.0) 0.001
Number of women (%) 17 (53.1%) 22 (28.2%) 6 (31.6%) 14 (70.0%) 0.002
Education (years) 10.7 (3.4) 11.5 (3.3) 10.0 (3.0) 10.0 (3.0) 0.147
Disease duration (years)a – 2.3 (1.9) 2.2 (1.9) 1.4 (1.0) 0.050
MMSE 28.8 (1.0) 27.7 (2.4) 23.3 (4.3) 23.4 (3.5) <0.001
UPDRS part III – 21.3 (9.9) 14.3 (11.4) 2.0 (2.5) <0.001
t-a-syn (pg/ml) 517 (215) 434 (223) 398 (148) 383 (147) 0.027
t-tau (pg/ml) 403 (236) 392 (310)b 469 (356) 678 (448) 0.212
t-tau/t-a-syn 0.77 (0.3) 0.87 (0.4)b 1.13 (0.7) 1.71 (0.8) <0.001
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination; NCs, normal controls; PD, Parkinson’s
disease; t-a-syn, total-a-synuclein; t-tau, total tau; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.Data are presented as mean (SD). P val-
ues for age, education, disease duration, MMSE and UPDRS were determined by Kruskal–Wallis H test, P value for sex was determined by
the Pearson chi-squared test and P values for CSF data were determined by ANCOVA, entering log-transformed CSF concentrations and adjust-
ing for age and sex.aTime from the patient recalling the ﬁrst symptoms to the clinical diagnosis; bN = 75.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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Table S2. Notably, MMSE was negatively correlated
with t-a-syn within NCs, PD and AD (only signiﬁcant
within NCs, q = 0.452, P = 0.010), but was posi-
tively correlated within DLB (q = 0.606, P = 0.006).
When exploring the t-tau/t-a-syn ratio, ANCOVA with
age and sex entered as covariates demonstrated signiﬁ-
cant diﬀerences between the groups (P < 0.001). Sim-
ple planned contrast analyses revealed signiﬁcant
diﬀerences between AD and NCs (P < 0.001) and
between AD and PD (P < 0.001, Fig. 1c, Table S3).
Across the disease groups, the t-tau/t-a-syn ratio was
lowest in PD. The diagnostic performance of t-a-syn,
t-tau and the ratio was determined by ROC curve
analysis (Table 2). Whilst the single CSF markers had
a fair or poor diagnostic performance, the t-tau/t-a-
syn ratio resulted in an improved diagnostic perfor-
mance for all group comparisons except PD versus
NCs (Fig. 2, Table 2). For example, for AD versus
DLB the AUC increased from 0.54 for t-a-syn (40%
sensitivity and 79% speciﬁcity) and 0.66 for t-tau
(70% sensitivity and 68% speciﬁcity) to 0.74 for the t-
tau/t-a-syn ratio (55% sensitivity and 95% speciﬁcity).
For PD versus AD the AUC increased from 0.58 for
t-a-syn (70% sensitivity and 54% speciﬁcity) and 0.73
for t-tau (70% sensitivity and 76% speciﬁcity) to 0.83
for the t-tau/t-a-syn ratio (70% sensitivity and 88%
speciﬁcity).
Discussion
The most important ﬁndings of this study, assessing
CSF levels of t-a-syn alone and combined with t-tau
in newly diagnosed patients with PD, DLB, AD and
NCs, are (i) that t-a-syn levels were signiﬁcantly lower
in PD, DLB and AD than in NCs but showed no sig-
niﬁcant diﬀerences between the disease groups, and
(ii) that the use of the t-tau/t-a-syn ratio instead of
the single markers signiﬁcantly improved the diagnos-
tic performance for most group comparisons.
Previous ﬁndings on CSF a-syn in PD, DLB and
AD have been inconsistent, which could be explained
by diﬀerences in pre-analytical sample handling,
Figure 1 Boxplots showing the CSF concentrations of t-a-syn (a), t-tau (b) and the t-tau/t-a-syn ratio (c) in NCs, PD, DLB and AD.
The P values are adjusted for age and sex.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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quantiﬁcation methods, inclusion criteria and level of
diagnostic evidence. This study makes a signiﬁcant
contribution to the ﬁeld through analysis of well-char-
acterized cohorts of patients with long clinical follow-
up period and strict inclusion and exclusion criteria,
standardized sample treatment, and our validated and
highly sensitive t-a-syn ELISA. Our ﬁndings match the
studies showing reduced t-a-syn concentrations in PD
versus NCs [6], and it was found that t-a-syn was also
signiﬁcantly lower in AD and DLB compared to NCs.
The decrease of CSF t-a-syn in PD and DLB may be
attributed to aggregation and deposition of t-a-syn into
LBs, their primary pathological hallmark. For AD, our
ﬁndings of reduced t-a-syn compared to NCs are in line
with reports by €Ohrfelt et al. [22] and Parnetti et al.
[23] who proposed a lower secretion into CSF due to
synaptic loss in AD. Many studies, however, have
reported t-a-syn levels in AD being about equal to or
slightly higher compared to NCs [9]. This discrepancy
might be caused by diﬀerences between the respective
AD cohorts. The AD patients in our study were newly
diagnosed and thus our ﬁndings might be reﬂective of
an early disease state. Interestingly, in our study, t-a-
syn tended to be higher in AD patients with lower
MMSE (correlation not signiﬁcant) and thus suppos-
edly with higher synaptic loss [24]. For DLB a positive
correlation between t-a-syn and MMSE was observed
which could indicate that synaptic loss has contributed
to the reduced t-a-syn levels in the DLB group.
For t-a-syn, no signiﬁcant diﬀerences between PD,
DLB and AD were found. Recent evidence suggests
that t-a-syn in combination with other markers can
provide discriminatory information between diseases
[7,23,25–29]. Tau and a-syn interact and promote each
other’s aggregation, and co-occurrence of tau and t-a-
syn inclusions are frequent in PD, DLB and AD [1]. A
positive correlation was found between t-a-syn and t-
tau which is in line with previous studies [7,25,28,30–
32]. Two previous studies have reported an improved
diagnostic performance using the t-tau/t-a-syn ratio in
distinguishing PD from controls [23,26]. In our study
with newly diagnosed, drug-na€ıve patients, it was found
that the t-tau/t-a-syn ratio did not improve the diagnos-
tic performance of NCs versus PD or DLB versus PD.
However, it is shown for the ﬁrst time that the t-tau/t-
a-syn ratio signiﬁcantly improved diagnostic perfor-
mance for NCs versus AD, PD versus AD and DLB
versus AD. Thus, the t-tau/t-a-syn ratio can strengthen
the AD core biomarker panel.
The strengths of this study are the strict inclusion
criteria for each diagnostic group and that patients
were diagnosed and followed by experienced move-
ment or dementia experts over a long time to ensure
highest diagnostic accuracy. All patients were newly
diagnosed and drug-na€ıve and thus at an early disease
stage, which is when the diﬀerential diagnosis is the
most diﬃcult. A limitation of this study is the rela-
tively small group sizes of the AD and DLB patients.
A panel of CSF markers consisting of t-tau, phos-
phorylated tau and Ab1–42 has been shown to corre-
late with AD pathology with high sensitivity and
speciﬁcity, and has had a large impact on the ﬁeld. A
counterpart that correlates well with a-syn pathology,
however, is still to be discovered. Our results validate
ﬁndings that the t-tau/t-a-syn ratio increases the diag-
nostic value of tau and t-a-syn, and should be
included in the development of a biomarker panel for
PD, DLB and AD. The identiﬁcation of a diagnostic
biomarker panel to improve the early and more accu-
rate diagnosis of these disorders will be tremendously
Table 2 Results of receiver operating characteristic curve analysis
t-a-syn t-tau t-tau/t-a-syn
NCs versus PD
AUC 0.625 0.550 0.560
P value 0.040 0.414 0.324
Sensitivity% 82.1 48.0 54.7
Speciﬁcity% 43.8 68.8 62.5
Cut-oﬀ value or ratio 556.6 295.4 0.74
NCs versus DLB
AUC 0.674 0.522 0.707
P value 0.039 0.793 0.014
Sensitivity% 78.9 26.3 73.7
Speciﬁcity% 56.3 87.5 68.8
Cut-oﬀ value or ratio 469.2 606.9 0.77
NCs versus AD
AUC 0.691 0.705 0.867
P value 0.022 0.013 <0.001
Sensitivity% 80.0 70.0 85.0
Speciﬁcity% 56.3 68.8 75.0
Cut-oﬀ value or ratio 474.6 461.2 0.92
PD versus DLB
AUC 0.545 0.572 0.644
P value 0.543 0.335 0.054
Sensitivity% 68.4 52.6 78.9
Speciﬁcity% 53.8 53.3 50.7
Cut-oﬀ value or ratio 404.3 327.3 0.76
PD versus AD
AUC 0.580 0.731 0.830
P value 0.271 0.002 <0.001
Sensitivity% 70.0 70.0 70.0
Speciﬁcity% 53.8 76.0 88.0
Cut-oﬀ value or ratio 402.3 465.9 1.29
DLB versus AD
AUC 0.542 0.663 0.739
P value 0.653 0.082 0.011
Sensitivity% 40.0 70.0 55.0
Speciﬁcity% 78.9 68.4 94.7
Cut-oﬀ value or ratio 302.1 451.7 0.74
AD, Alzheimer’s disease; AUC, area under the curve; DLB, demen-
tia with Lewy bodies; NCs, normal controls; PD, Parkinson’s dis-
ease; t-a-syn, total-a-synuclein; t-tau, total tau.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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important for early diagnosis, patient management
and clinical trials.
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